Therefore, we anticipated that the strategy of conjugating CHP to PTX@HSA NPs could open new avenues for current endovascular treatment of atherosclerosis and provide a new solution for molecular therapy of atherosclerotic plaques. This evidence concerns the gene ALB and atherosclerosis.